Back to today’s briefing

Story perspectives

FDA Tightens COVID-19 Vaccine Access for Younger Adults

5/20/2025

44 6

Summary

FDA Vaccine Restrictions

The FDA is restricting COVID-19 vaccine approvals to adults over 65 and those with health conditions starting this fall.
Healthy individuals under 65 will face stricter access requirements, necessitating extensive studies for approval.
This policy aims to align U.S. guidelines with international standards and rebuild public trust in vaccines.
An estimated 100-200 million Americans may still be eligible for vaccines under the revised criteria.

Summary

FDA Approves Novavax

The FDA fully approved Novavax's COVID-19 vaccine, Nuvaxovid, for adults 65+ and high-risk individuals aged 12-64.
A Phase 4 trial is required for those aged 50-64 without high-risk conditions.
Sanofi will receive a $175 million payment for marketing responsibilities.
Novavax plans to provide commercial doses by fall 2025, subject to FDA strain recommendations.

1 of 2

FDA Vaccine Restrictions

The FDA is restricting COVID-19 vaccine approvals to adults over 65 and those with health conditions starting this fall.
Healthy individuals under 65 will face stricter access requirements, necessitating extensive studies for approval.
This policy aims to align U.S. guidelines with international standards and rebuild public trust in vaccines.
An estimated 100-200 million Americans may still be eligible for vaccines under the revised criteria.

1 / 2